Blair William & Co. IL increased its holdings in shares of Assembly Biosciences Inc (NASDAQ:ASMB) by 87.1% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,913 shares of the biopharmaceutical company’s stock after purchasing an additional 6,013 shares during the quarter. Blair William & Co. IL owned 0.06% of Assembly Biosciences worth $635,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also bought and sold shares of ASMB. Schwab Charles Investment Management Inc. increased its position in Assembly Biosciences by 34.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 31,400 shares of the biopharmaceutical company’s stock worth $1,421,000 after purchasing an additional 8,000 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $242,000. Swiss National Bank acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $1,281,000. The Manufacturers Life Insurance Company increased its position in Assembly Biosciences by 12.2% during the 4th quarter. The Manufacturers Life Insurance Company now owns 12,371 shares of the biopharmaceutical company’s stock worth $560,000 after purchasing an additional 1,349 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Assembly Biosciences by 34.9% during the 4th quarter. Bank of New York Mellon Corp now owns 63,821 shares of the biopharmaceutical company’s stock worth $2,887,000 after purchasing an additional 16,504 shares in the last quarter. 78.11% of the stock is owned by hedge funds and other institutional investors.
ASMB opened at $44.18 on Monday. The company has a market cap of $939.37 million, a P/E ratio of -18.33 and a beta of 0.79. Assembly Biosciences Inc has a 1 year low of $18.60 and a 1 year high of $67.36.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Monday, May 7th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.11). Assembly Biosciences had a negative net margin of 379.22% and a negative return on equity of 56.56%. The firm had revenue of $3.57 million during the quarter, compared to analyst estimates of $1.88 million. analysts expect that Assembly Biosciences Inc will post -3.54 earnings per share for the current year.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the stock in a transaction that occurred on Tuesday, May 1st. The shares were sold at an average price of $43.06, for a total value of $43,060.00. Following the completion of the sale, the director now owns 20,465 shares of the company’s stock, valued at $881,222.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 3,000 shares of company stock valued at $134,850 in the last ninety days. 18.20% of the stock is owned by corporate insiders.
A number of research firms recently issued reports on ASMB. Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 14th. Chardan Capital downgraded shares of Assembly Biosciences from a “buy” rating to a “neutral” rating and increased their target price for the stock from $35.00 to $50.00 in a research report on Friday, April 13th. BidaskClub downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 23rd. B. Riley dropped their target price on shares of Assembly Biosciences to $45.00 and set a “neutral” rating for the company in a research report on Tuesday, May 8th. Finally, ValuEngine raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $60.50.
Assembly Biosciences Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.